MORRISVILLE, North Carolina, January 16, 2012 /PRNewswire/ --
- Reveal® Data May Set New Standard for Monitoring
nContact, Inc., the leading innovator in epicardial ablation devices, today announced that data presented by physicians in two posters at the 17th Annual International Boston Atrial Fibrillation Symposium may change how physicians think about treating atrial fibrillation patients with enlarged atria. These posters included outcomes from a single European site at the University Medical Center in Ljubljana, Slovenia as presented by Prof. Borut Gersak, MD, PhD., Chief of Department of Cardiac Surgery at University Medical Center Ljubljana, and a multi-center U.S. data collection led by Eric Prystowsky, MD, FACC, of St. Vincent Hospital in Indianapolis and presented by Keith Golden, MD, also of St. Vincent Hospital. Physicians performed the interdisciplinary Convergent Procedure in a challenging patient population with persistent and longstanding persistent AF, utilizing high monitoring standards to document procedural outcomes.
Poster: Prospective Reveal® XT Outcomes for the Convergent Atrial Fibrillation Ablation Procedure; Gersak et al.
"Historically, surgical approaches have proven too invasive to attract cardiology referrals for standalone AF treatment. Surgeons are not the recognized experts in electrophysiology, and do not have the EP diagnostic and ablation technologies to assure a comprehensive and predictive approach to treatment," said Prof. Gersak.
Continuing his comments, Prof. Gersak said, "With the support of our EP team, Medtronic's Reveal 24-hour loop recorders were implanted in fifty patients undergoing the Convergent procedure to determine the long term success of the procedure by continuously recording rhythm status. The surgical portion of the procedure requires no chest incisions or ports, no lung deflation or heart incisions, and takes about 1 1/2 hours to perform. Access to the posterior of the atrium is through the diaphragm and a small incision in the abdomen. This access is named SUBTLE™, or 'sub-thoracic total endoscopic' and provides direct visibility to place the ablation device and assure lesion connectivity. Of the fifty patients treated, 94% had persistent or longstanding persistent AF. At six, twelve and twenty-four month follow-up, 95%, 91%, and 87% of patients, respectively, were in sinus rhythm, with only one patient requiring a repeat catheter ablation procedure. AF burden of less than or equal to 3% was recorded in 81%, 84%, and 87% of patients over six, twelve, and twenty-four months respectively. The outcomes, as recorded by the Reveal technology, may set a new monitoring standard for comparative ablation approaches."
Poster: Multicenter Retrospective Outcomes for the Treatment of Atrial Fibrillation Using the Multidisciplinary Convergent Procedure; Golden et al.
The poster reported by Dr. Golden indicated that 115 patients underwent the Convergent Procedure across four U.S. centers and of these, 97 were followed for an average of 11.4 months using a 72 hour Holter monitor. Eighty-four percent (84%) of the patients were in sinus rhythm and 77% were in sinus rhythm off anti-arrhythmic dugs (ADDs) or had no change in AAD prophylaxis almost one year post procedure.
Dr. Jeff Olson, an EP Cardiologist who has been a primary contributor to the Convergent Procedure experience at St. Vincent Hospital, said "It is hoped that by standardizing the evolving Convergent Procedure and patient selection, future sites may expect the same results. The Convergent Procedure is an important ablation option for persistent and longstanding persistent patients in our practice. We believe the multi-disciplinary procedure offers a comprehensive approach that neither discipline can attain individually. It has substantially reduced EP procedure times, complexity and the amount of ablation required."
nContact's Numeris® Coagulation System with VisiTrax® and next generation EPi-Sense® Coagulation System technology integrate suction, perfusion, and radiofrequency energy to ensure consistent cardiac tissue contact and create visible, continuous lesions on the epicardium of a beating heart. For more information, please visit http://www.ncontactinc.eu.
About nContact, Inc.
nContact, Inc. is the leading innovator in epicardial ablation devices and techniques, dedicated to transforming the underserved arrhythmia market through the advancement of less invasive, more efficacious ablation alternatives for cardiac arrhythmias such as atrial fibrillation (AF).
Its lead technologies, the EPi-Sense® and Numeris® Coagulation System with VisiTrax®, have CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter.
The Numeris® Coagulation System with VisiTrax® is also indicated for endoscopic coagulation of cardiac tissue in the United States. nContact was founded in 2005 and is headquartered in Morrisville, North Carolina, U.S.A.
FOR INTERNATIONAL RELEASE ONLY
SOURCE nContact, Inc.